Novo Nordisk CEO: side-effects not a problem in CagriSema study
Novo Nordisk's CEO said on Wednesday side-effects were not a problem in the trial of its next-generation obesity drug candidate CagriSema as the company considers dosage escalation and trial length for a new study.
Novo Nordisk’s Wegovy Drug Sales Miss Expectations
The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter despite more than doubling on the year.
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current best-selling drug in this area, Wegovy, to shame. Let's look deeper into these results and what they could mean for investors.
Obesity drug sales help Novo Nordisk beat expectations
Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping the Danish drugmaker beat revenue expectations.
Novo Nordisk to seek regulatory approval for CagriSema obesity drug early 2026
Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the first quarter of next year, slightly later than its previous expectation to file towards end-2025.
Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs
Novo Nordisk's Karsten Munk Knudsen is targeting 800 million obese people globally.
Novo Nordisk says it's not immune to potential Trump tariffs, but business is well-positioned
Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, ...
Novo Nordisk sales beat estimates, but the story wasn’t Ozempic
Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...
devdiscourse1h
Novo Nordisk's Bold Step: Tackling Dosage Challenges in Obesity Drug Trials
Novo Nordisk's next-gen obesity drug, CagriSema, faces trial challenges with dosage flexibility and trial length as side-effects remain controlled. Investor skepticism arose from weaker-than-expected ...
Wegovy sales double to boost Novo Nordisk's fourth quarter but slower growth predicted
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...
Novo Nordisk Foundation Will Not Fill Funding Gaps
Novo’s record profit from obesity drugs has given the Foundation a war chest to fund its philanthropic grants, although ...
Stocks to Watch Wednesday: AMD, Alphabet, Novo Nordisk
A slowdown in Google's cloud-computing sales helped drag down Alphabet's overall revenue growth to its lowest rate since 2023. Shares tumbled about 7% ...
Wegovy maker Novo Nordisk says surging growth driving emissions higher
Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...